State Key Laboratory of Genetic Engineering, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China.
Cambridge-Suda Genomic Resource Center and Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, Soochow University, Suzhou, China.
Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-negative breast cancer patient who later was administrated with a PARP inhibitor for 2 months. We demonstrated in cell and mouse models that, compared to the wild-type, (1) c.403G>A mutant cell lines were more sensitive to irradiation, a DNA damage agent, and a PARP inhibitor; (2) c.403G>A mutation inhibited interaction between BARD1 and RAD51 (but not BRCA1); and (3) c.403G>A mutant mice were hypersensitive to ionizing radiation. Our study shed lights on the clinical interpretation of rare germline mutations of BARD1.
我们通过对一位早发性三阴性乳腺癌患者的种系和肿瘤样本进行基因组学和转录组学综合分析,发现了 BARD1 中一个罕见的错义种系突变(c.403G>A 或 p.Asp135Asn),该突变被认为是致病性的。该患者后来接受了 2 个月的 PARP 抑制剂治疗。我们在细胞和小鼠模型中证明,与野生型相比,(1)c.403G>A 突变细胞系对辐射(一种 DNA 损伤剂和 PARP 抑制剂)更敏感;(2)c.403G>A 突变抑制了 BARD1 和 RAD51 之间的相互作用(但不抑制 BRCA1);(3)c.403G>A 突变小鼠对电离辐射更敏感。我们的研究为 BARD1 罕见种系突变的临床解释提供了线索。